Abstract:Here, we report KTX207, a previously undescribed cereblon‐based PDE4 PROTAC that can specifically target PDE4D shortform for degradation. We showed that KTX207 could improve selectivity, potency and enable a long‐lasting effect when used at a sub‐nanomolar concentration. A significant decline in cell growth and TNF‐α inhibition pinpointed the anti‐proliferative and anti‐inflammatory effects of KTX207. Our work highlights the advantages of targeted degradation to establish isoform specificity, which represents an evolution in the development of PDE4 inhibitors. Cyclic AMP (cAMP) has a crucial role in many vital cellular processes and there has been much effort expended in the discovery of inhibitors against the enzyme superfamily that degrades this second messenger, namely phosphodiesterases (PDEs). The journey of competitive PDE inhibitors to the clinic has been hampered by side effects profiles that have resulted from a lack of selectivity for subfamilies and individual isoforms because of high conservation of catalytic site sequences and structures. Here we introduce a proteolysis targeting chimera (PROTAC) that can specifically target a small subset of isoforms from the PDE4 family to send the enzyme for degradation at the proteasome by recruiting a ubiquitin E3 ligase into proximity with the PDE. We constructed our PDE4 PROTAC (KTX207) using a previously characterized PDE4 inhibitor, and we show that evolution of the compound into a PROTAC improves selectivity, potency and enables a long‐lasting effect even after the compound is removed from cells after a short treatment duration. Functionally, KTX207 is more effective at increasing cAMP, is 100 times more anti‐inflammatory, and is significantly better at reducing the growth in cancer cell models than the PDE4 inhibitor alone. Our study highlights the advantages of targeted degradation versus active‐site occupancy for PDE4 inhibition and discusses the potential of this novel pharmacological approach to improve the safety profile of PDE4 inhibition in the future.

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Targeted Degradation of Protein Kinase A via a Stapled Peptide PROTAC

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Development of Selective Mono or Dual PROTAC Degrader Probe of CDK Isoforms.

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation